Lawrence Steinman, MD

Publication Details

  • An immunomodulatory GpG oligonucleotide for the treatment of autoimmunity via the innate and adaptive immune systems JOURNAL OF IMMUNOLOGY Ho, P. P., Fontoura, P., Ruiz, P. J., Steinman, L., Garren, H. 2003; 171 (9): 4920-4926


    Bacterial DNA and immunostimulatory CpG oligodeoxynucleotides (ODNs) activate the innate immune system to produce proinflammatory cytokines. Shown to be potent Th1-like adjuvants, stimulatory CpG motifs are currently used as effective therapeutic vaccines for various animal models of infectious diseases, tumors, allergies, and autoimmune diseases. In this study, we show that the application of an immunomodulatory GpG ODN, with a single base switch from CpG to GpG, can effectively inhibit the activation of Th1 T cells associated with autoimmune disease. Moreover, this immunomodulatory GpG ODN suppresses the severity of experimental autoimmune encephalomyelitis in mice, a prototypic Th1-mediated animal disease model for multiple sclerosis.

    View details for Web of Science ID 000186136800056

    View details for PubMedID 14568974

Stanford Medicine Resources:

Footer Links: